CTLA4 and Miyoshi myopathy: For MM, the US Food and Drug Administration has approved use of anti-PD-1 (nivolumab and pembrolizumab), anti-cytotoxic T-lymphocyte associated protein (CTLA)-4 (ipilimumab), and anti-PD-1/anti-CTLA-4 combination therapies (Pardoll, 2012).